Lundbeck Seattle Biopharmaceuticals
Pharmaceutical development company
From Wikipedia, the free encyclopedia
Lundbeck Seattle Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Formerly known as Alder Biopharmaceuticals, it specializes in therapeutic monoclonal antibodies.
| |
| Formerly | Alder Biopharmaceuticals |
|---|---|
Company type | Subsidiary |
| Founded | 2004 |
| Headquarters | , |
| Parent | Lundbeck |
| Website | https://www.lundbeck.com/us/about-us/lundbeck-in-the-us |
Overview
In May 2014, Alder went public.[1] In early 2018, the company made a public stock offering, aiming to raise US$250 million.[2] The company identifies, develops, and manufactures antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular, and autoimmune and inflammatory disease areas.[3]
As of September 2019, the Alder Biopharmaceuticals shares have increased with 83% in price, following the company's acquisition by the Denmark-based H. Lundbeck, in a deal valued at $1.95 billion.[4][5] The company subsequently changed its name to Lundbeck Seattle Biopharmaceuticals after the acquisition.[6]
